Skip to content

Ocular Imaging With Spectral Domain Optical Coherence Tomography

Posterior and Anterior Ocular Imaging With Spectral Domain Optical Coherence Tomography

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00926549
Enrollment
300
Registered
2009-06-23
Start date
2009-05-31
Completion date
2009-09-30
Last updated
2009-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Hypermetropia, Myopia

Keywords

spectral domain-OCT, macular thickness, myopia, hypermetropia, normal

Brief summary

The purpose of this study is to analyze macular retinal thickness and macular volume using the spectral domain - optical coherence tomography (SD-OCT) in normal eyes and in eyes with various ocular diseases.

Detailed description

Assessment of macular thickness is important for the treatment and follow-up of a variety of ocular diseases. The introduction of optical coherence tomography (OCT) has enabled clinicians to reliably detect small changes in macular thickness and to quantitatively evaluate the efficacy of different therapeutic modalities. In this study using the spectral domain-OCT, we examined the variations of macular retinal thickness and macular volume in normal eyes and in eyes with various ocular diseases.

Interventions

DEVICESpectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)

macular cube scanning

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* normal eyes * myopic eyes * hypermetropic eyes

Exclusion criteria

* systemic illness * cataract * previous ocular trauma or surgery(other than cataract surgery or refractive surgeries)

Design outcomes

Primary

MeasureTime frame
macular retinal thickness and volume3 months

Countries

South Korea

Contacts

Primary ContactSung Soo Kim, MD, PhD
semekim@naver.com82-2-2019-3443
Backup ContactWon Kyung Song, MD
songwk@yuhs.ac82-2-2228-3591

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026